Page 3 - Daniel Mackey News Today

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2021 Message from the CEO IBT is conducting a phase III-study ("The Connection Study") which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing Lactobacillus reuteri as active substance. The active substance is a human bacterial strain found naturally in breast milk. The objective of the study is to show that the active substance can prevent necro...

At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2021, among other things, the following was resolved: adoption of the annual reportthat no dividend is givendischarge

Infant Bacterial Therapeutics Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams Infant Bacterial Therapeutics expands The Connection Study to include infants with a birth weight below 750 grams A l ment criteria of The Connection Study to include 500 - 1000 gram birth weight premature infants.   The Data Monitoring Committee (DMC) has performed a per protocol predefined safety and tolerability assessment of the first 300 patients...

Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics receives additional patent protection in China Infant Bacterial Therapeutics AB (IBT) today announces that the Chinese patent office has issued a decision to grant approval of IBTs patent application entitled: A method of activating lactic acid bacteria, which protects formulations of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improve...

Infant Bacterial Therapeutics AB: Infant Bacterial Therapeutics publishes Annual Report for 2020 The report is available on IBTs website ibtherapeutics.comunder the section "Investors & Media - Financial Reports" and is available in printed form for those that have requested. A copy can be requested by contacting IBTs office via info@ibtherapeutics.com. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage wi...

Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants. The ...

Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk.  This message from the CEO is written during the continuing COVID-19 pandemic which now has been ongoing for one year. The pandemic appeared to be under control during the f...

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - December 31, 2020 Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk. This message from the CEO is written during the continuing COVID-19 pande...